Cerebral venous thrombosis: a practical review

Postgrad Med J. 2024 Jan 21;100(1180):68-83. doi: 10.1093/postmj/qgad103.

Abstract

The evolution of the Coronavirus Disease-2019 pandemic and its vaccination raised more attention to cerebral venous thrombosis (CVT). Although CVT is less prevalent than arterial stroke, it results in larger years of life lost. CVT is more common in women and young patients. Predisposing factors are categorized as transient factors such as pregnancy, puerperium, oral contraceptive pills, trauma, and dehydration; and permanent factors such as neoplastic, vasculitic, thrombophilic, hematologic conditions, infectious causes such as severe acute respiratory syndrome coronavirus-2 infection and HIV. The most common manifestations are headache, seizures, focal neurologic deficits, altered level of consciousness, and cranial nerve palsies. The most common syndromes are stroke-like, raised-intracranial-pressure (ICP), isolated-headache, and encephalopathy, which may have overlaps. Diagnosis is mostly based on computed tomography, magnetic resonance imaging, and their respective venous sequences, supported by blood results abnormalities such as D-dimer elevation. Treatment includes the prevention of propagation of current thrombus with anticoagulation (heparin, or low molecular weight heparinoids and then warfarin, or direct oral anticoagulants), decreasing ICP (even by decompressive craniotomy), and treatment of specific underlying diseases.

Keywords: cerebral venous thrombosis; cerebrovascular disease; diagnosis; sinus thrombosis; treatment.

MeSH terms

  • Anticoagulants / therapeutic use
  • Female
  • Headache / complications
  • Humans
  • Intracranial Thrombosis* / diagnostic imaging
  • Intracranial Thrombosis* / drug therapy
  • Pregnancy
  • Stroke* / complications
  • Venous Thrombosis* / diagnosis
  • Venous Thrombosis* / drug therapy
  • Venous Thrombosis* / etiology

Substances

  • Anticoagulants